﻿<?xml version="1.0" encoding="utf-8"?><?xml-stylesheet title="XSL_formatting" type="text/xsl" href="cms1260795.aspx"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><language>en-gb</language><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><lastBuildDate>Sat, 22 Nov 2008 00:27:58 GMT</lastBuildDate><title><![CDATA[aidsmap.com news feed : Mexico 2008 news]]></title><description><![CDATA[aidsmap.com news feed : Mexico 2008 news]]></description><copyright>Copyright NAM 2008</copyright><link>http://www.aidsmap.com</link><atom:link href="http://www.aidsmap.com/cms1266297.aspx" rel="self" type="application/rss+xml" /><image><title><![CDATA[aidsmap.com news feed : Mexico 2008 news]]></title><url>http://www.aidsmap.com/files/file1002517.gif</url><link>http://www.aidsmap.com</link><width>122</width><height>44</height></image><ttl>15</ttl><item><title><![CDATA[Justice Edwin Cameron calls for a campaign against 'misguided criminal laws and prosecutions']]></title><link>http://www.aidsmap.com/en/news/D2C8CE4E-E341-445F-87AE-4947D64F6CF0.asp</link><author>Edwin J. Bernard</author><guid isPermaLink="false">D2C8CE4E-E341-445F-87AE-4947D64F6CF0</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[“HIV is a virus, not a crime,” argued South African Supreme Court Justice Edwin Cameron during his impassioned call for “a campaign against criminalisation” on the final day of the XVII International AIDS Conference in Mexico City. 
]]></description><category>Middle East news</category><category>HIV and the law news</category><category>Africa news</category><category>Conference news</category><category>Women and HIV news</category><category>Developed world news</category><category>Prevention news</category><category>Asia and Pacific news</category><category>Community involvement news</category><category>Mexico 2008</category><category>World policy News</category></item><item><title><![CDATA[Incidence increasing of HIV-associated multicentric Castleman's disease, a relatively rare lymphatic cancer]]></title><link>http://www.aidsmap.com/en/news/1B51F594-075A-40A1-B3D2-7DBB8AF10A52.asp</link><author>Edwin J. Bernard</author><guid isPermaLink="false">1B51F594-075A-40A1-B3D2-7DBB8AF10A52</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Increasing numbers of cases of the relatively rare lymphatic cancer, multicentric Castleman's disease, are being diagnosed in HIV-positive individuals attending the UK’s largest HIV clinic, according to a presentation to the XVII International AIDS Conference in Mexico City earlier this month by Dr Mark Bower of London’s Chelsea and Westminster Hospital. 
]]></description><category>HIV and cancer news</category><category>Conference news</category><category>Mexico 2008</category></item><item><title><![CDATA[Next generation first-line NNRTI, rilpivirine (TMC278) potent; lowest dose better-tolerated than efavirenz at 96 weeks]]></title><link>http://www.aidsmap.com/en/news/4458BE13-A6E2-49CA-B795-F5FA101509F2.asp</link><author>Edwin J. Bernard</author><guid isPermaLink="false">4458BE13-A6E2-49CA-B795-F5FA101509F2</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Tibotec’s next-generation NNRTI, rilpivirine (previously known as TMC278) continues to suppress viral load and increase CD4 counts in similar numbers of treatment-naïve patients to efavirenz (Sustiva) over 96 weeks according to Phase IIb study data presented to the recent XVII International AIDS Conference in Mexico City. When compared to efavirenz, however, rilpivirine appears to produce a lower incidence of rash, central nervous system disorders, and lipid abnormalities.
]]></description><category>New drugs news</category><category>Conference news</category><category>Mexico 2008</category></item><item><title><![CDATA[`Express care` by nurses for people starting HIV treatment decreases clinic congestion, and may improve outcomes]]></title><link>http://www.aidsmap.com/en/news/5B3AA43E-4B05-475D-B6C6-D5279143467B.asp</link><author>Theo  Smart</author><guid isPermaLink="false">5B3AA43E-4B05-475D-B6C6-D5279143467B</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA['Express care', a new model for providing care to people starting antiretroviral therapy in which most of the burden for seeing patients is shifted to nurses, is associated with reduced death rates (by about 50%) and reduced losses to follow-up among people with CD4 cell counts of less than 100 cells/mm3, according to a Kenyan presentation made earlier this month at the International AIDS Conference, in Mexico City. 
]]></description><category>Africa news</category><category>Conference news</category><category>Mexico 2008</category><category>Treatment access news</category></item><item><title><![CDATA[Heat-stable ritonavir tablet equivalent to soft gel capsule; may be approved next year]]></title><link>http://www.aidsmap.com/en/news/D097D2DF-76CF-4887-9CDA-E7A1414E3FF3.asp</link><author>Edwin J. Bernard</author><guid isPermaLink="false">D097D2DF-76CF-4887-9CDA-E7A1414E3FF3</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[A new 100 mg tablet formulation of the protease inhibitor ritonavir (Norvir) appears to be equivalent to the current soft-gel capsule formation in terms of side-effects and boosting potential, according to data presented to the XVII International AIDS Conference in Mexico City last week. The new tablet formulation, which like the Kaletra tablet, is heat-stable and does not require refrigeration, will be submitted for registration in the US and EU by the end of the year, says its developer, Abbott.
]]></description><category>Pharmacokinetics news</category><category>Conference news</category><category>New drugs news</category><category>Mexico 2008</category><category>Side-effects news</category></item><item><title><![CDATA[Erection loss with condoms predicts subsequent unsafe sex]]></title><link>http://www.aidsmap.com/en/news/6FF03986-8B03-4B28-9557-09AD70018297.asp</link><author>Gus Cairns</author><guid isPermaLink="false">6FF03986-8B03-4B28-9557-09AD70018297</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[If gay men experience erection loss when they use condoms for insertive anal sex, they are both less likely to use condoms over the following six months, and less likely to intend to use condoms, Dutch researchers have found. So called COINED - COndom INduced Erectile Dysfunction – was such a strong independent predictor of subsequent premeditated, as opposed to unpremeditated, unprotected sex, the researchers found, that it could be used as a ‘surrogate marker’ for it.  
]]></description><category>Conference news</category><category>Gay men news</category><category>Prevention news</category><category>Mexico 2008</category></item><item><title><![CDATA[Uptake of second-line treatment `stagnant` in developing world]]></title><link>http://www.aidsmap.com/en/news/E7B6C653-D3BE-4C24-873D-25B23F168BB0.asp</link><author>Keith Alcorn</author><guid isPermaLink="false">E7B6C653-D3BE-4C24-873D-25B23F168BB0</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[The uptake of second-line antiretroviral treatment in developing countries is `stagnant` according to a survey by the World Health Organization presented at last week’s XVII International AIDS Conference, despite substantial cuts in drug prices over the past 18 months.
]]></description><category>Africa news</category><category>Changing treatments news</category><category>Conference news</category><category>Mexico 2008</category><category>Treatment access news</category></item><item><title><![CDATA[Ethnic minority gay men in UK have very different rates of HIV infection despite similar behaviours]]></title><link>http://www.aidsmap.com/en/news/6A562BFB-44F1-4CC5-A27B-5DECB16FDBA7.asp</link><author>Gus Cairns</author><guid isPermaLink="false">6A562BFB-44F1-4CC5-A27B-5DECB16FDBA7</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[The largest study to date on ethnic minority gay men and men who have sex with men (MSM) in the UK has found significant variations in rates of HIV infection between ethnic groups despite similar rates of sexual risk behaviour. Professor Jonathan Elford of City University, London presented his findings to the satellite conference on MSM and HIV preceding the International AIDS Conference in Mexico, and his team added more data in posters presented to the main conference. 
]]></description><category>Conference news</category><category>Gay men news</category><category>Mexico 2008</category></item><item><title><![CDATA[Three per cent of TB cases in Lisbon found to be extensively drug-resistant]]></title><link>http://www.aidsmap.com/en/news/24E577FC-9243-448E-872E-0B5881D57ADA.asp</link><author>Derek Thaczuk</author><guid isPermaLink="false">24E577FC-9243-448E-872E-0B5881D57ADA</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Three per cent of TB cases diagnosed at one of Lisbon’s major hospitals between 2003 and 2007 were extensively drug-resistant, and there was a strong correlation between HIV infection or hepatitis C infection and extensively drug-resistant TB, Portuguese researchers reported last week at the XVII International AIDS Conference in Mexico City.
]]></description><category>Conference news</category><category>Mexico 2008</category><category>Tuberculosis news</category></item><item><title><![CDATA[One in five patients at London clinic are lost to follow-up and do not attend elsewhere in the UK]]></title><link>http://www.aidsmap.com/en/news/6DAD7BD0-0AF3-41A5-918D-4AB2ACC14351.asp</link><author>Roger Pebody</author><guid isPermaLink="false">6DAD7BD0-0AF3-41A5-918D-4AB2ACC14351</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[The numbers of patients at a busy south London HIV clinic who do not return for appointments or to collect prescriptions is comparable to rates reported in sub-Saharan Africa, according to a study presented by Sarah Gerver at the International AIDS Conference in Mexico City on August 5th. Four in ten patients are lost to follow-up, and more than half of these patients could not be traced to other HIV clinics in the UK.
]]></description><category>Adherence news</category><category>UK news</category><category>Developed world news</category><category>Mexico 2008</category></item><item><title><![CDATA[Hepatitis C coinfection may increase the risk of heart attacks and strokes in people with HIV]]></title><link>http://www.aidsmap.com/en/news/EB478F92-FD9D-44A5-BC2C-32604D28D598.asp</link><author>Liz Highleyman</author><guid isPermaLink="false">EB478F92-FD9D-44A5-BC2C-32604D28D598</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Coinfection with hepatitis C virus (HCV) may be associated with an increased risk of cardiovascular events such as heart attacks and strokes, even though people with hepatitis C have lower cholesterol levels, according to a study presented on Thursday at the XVII International AIDS Conference in Mexico City.
]]></description><category>Hepatitis news</category><category>Conference news</category><category>Mexico 2008</category></item><item><title><![CDATA[Occult hepatitis B is more common in people with HIV, but occult hepatitis C is rare]]></title><link>http://www.aidsmap.com/en/news/73E54182-9ECE-4BC6-9043-89100B60D844.asp</link><author>Liz Highleyman</author><guid isPermaLink="false">73E54182-9ECE-4BC6-9043-89100B60D844</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Occult or hidden hepatitis B virus (HBV) infection was strongly linked to HIV-related immune suppression in a cohort of US women, but occult hepatitis C virus (HCV) infection was rare, according to a presentation on Thursday at the XVII International AIDS Conference.
]]></description><category>Conference news</category><category>Hepatitis news</category><category>Mexico 2008</category></item><item><title><![CDATA[Monkey study strengthens the case for a microbicide combining several anti-HIV drugs]]></title><link>http://www.aidsmap.com/en/news/B24C79EE-D458-4417-BEBA-3564BA02B2E2.asp</link><author>Gus Cairns</author><guid isPermaLink="false">B24C79EE-D458-4417-BEBA-3564BA02B2E2</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[A study using a microbicide gel containing the antiretroviral drugs in the combination pill Truvada – tenofovir and FTC (emtricitabine) – completely protected six pigtail macaque monkeys from infection with a type of HIV designed to be infectious to monkeys, the XVII International AIDS Conference heard on Thursday.
]]></description><category>Conference news</category><category>Mexico 2008</category><category>Prevention news</category></item><item><title><![CDATA[Systematic review unable to confirm or deny Swiss statement on infection risk with undetectable viral load]]></title><link>http://www.aidsmap.com/en/news/F2E2BCFF-26CF-4400-B5AC-0549FBAC940D.asp</link><author>Edwin J. Bernard</author><guid isPermaLink="false">F2E2BCFF-26CF-4400-B5AC-0549FBAC940D</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[A systematic review of studies of serodiscordant couples where the HIV-positive partner was on antiretroviral treatment could neither confirm not disprove the recent Swiss declaration of a negligible risk of HIV transmission from a pesron on treatment with undetectable viral load, according to data presented during Thursday afternoon’s late breaker sessions at the XVII International AIDS Conference in Mexico City. 
]]></description><category>Conference news</category><category>Prevention news</category><category>Basic science news</category><category>Mexico 2008</category></item><item><title><![CDATA[Two new NNRTIs look promising in early clinical trials]]></title><link>http://www.aidsmap.com/en/news/18A8C416-4BD7-4060-A556-46EAB9271E04.asp</link><author>Liz Highleyman</author><guid isPermaLink="false">18A8C416-4BD7-4060-A556-46EAB9271E04</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Two new non-nucleoside reverse transcriptase inhibitors (NNRTIs) have demonstrated good antiviral efficacy and favourable safety profiles in seven-day monotherapy trials, according to late-breaker presentations on Thursday at the XVII International AIDS Conference in Mexico City.
]]></description><category>New drugs news</category><category>Conference news</category><category>Mexico 2008</category></item><item><title><![CDATA[Which gay men should be the target for prevention work?]]></title><link>http://www.aidsmap.com/en/news/59F245B0-B92E-43B6-97AF-69BE76393815.asp</link><author>Roger Pebody</author><guid isPermaLink="false">59F245B0-B92E-43B6-97AF-69BE76393815</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Researchers at the International AIDS Conference in Mexico City have suggested a range of approaches for better defining the characteristics of gay men who are at greatest risk of being involved in HIV exposure or transmission, and who can be targeted for HIV prevention interventions.
]]></description><category>Conference news</category><category>Gay men news</category><category>Mexico 2008</category><category>Prevention news</category></item><item><title><![CDATA[High prevalence of hepatitis C in Dutch HIV-positive gay men ]]></title><link>http://www.aidsmap.com/en/news/E1C8AF48-6802-4918-A8BF-6EAD1FA5A559.asp</link><author>Roger Pebody</author><guid isPermaLink="false">E1C8AF48-6802-4918-A8BF-6EAD1FA5A559</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[The prevalence of hepatitis C infection among HIV-positive gay men attending a large Amsterdam sexual health clinic is 18% and rising, reported Anouk Urbanus at the XVII International AIDS Conference in Mexico City on August 7th.
]]></description><category>Gay men news</category><category>Hepatitis news</category><category>Conference news</category><category>Mexico 2008</category><category>HIV and sexual health news</category></item><item><title><![CDATA[Protective effect of circumcision is sustained for at least 3.5 years; also works against HPV]]></title><link>http://www.aidsmap.com/en/news/34F3DFB7-10DF-4956-8798-9F8C6DBB33FE.asp</link><author>Gus Cairns</author><guid isPermaLink="false">34F3DFB7-10DF-4956-8798-9F8C6DBB33FE</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[The protective effect of circumcision against HIV infection remains unchanged for at least 42 months after the operation, the lead investigator from the randomised controlled trial (RCT) in Kisumu, Kenya, told the XVII International AIDS Conference on Thursday in Mexico City.
]]></description><category>Africa news</category><category>Conference news</category><category>HIV and sexual health news</category><category>Mexico 2008</category><category>Circumcision news</category></item><item><title><![CDATA[Men more likely to drop out of clinic care than women in western Kenya]]></title><link>http://www.aidsmap.com/en/news/94A663D0-112C-4E4D-B6A1-B9365DF2B168.asp</link><author>Theo  Smart</author><guid isPermaLink="false">94A663D0-112C-4E4D-B6A1-B9365DF2B168</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Men are at much higher risk of becoming lost from HIV care programmes according to an analysis of clients attending USAID-AMPATH partnership’s HIV clinics in Western Kenya. This study, which also identified reasons why both men and women may be at risk of loss to follow-up (LTFU), was presented on Tuesday at the XVII International AIDS Conference in Mexico City.
]]></description><category>Africa news</category><category>Adherence news</category><category>Conference news</category><category>Mexico 2008</category></item><item><title><![CDATA[How does abacavir/3TC compare to tenofovir/FTC? ACTG5202 and GSK studies disagree]]></title><link>http://www.aidsmap.com/en/news/6A8BAFF8-1486-4553-812A-E2F9763B886B.asp</link><author>Derek Thaczuk</author><guid isPermaLink="false">6A8BAFF8-1486-4553-812A-E2F9763B886B</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Contradictory findings regarding the safety and efficacy of the dual-nucleoside combination of abacavir and 3TC were presented in a late-breaker session at the XVII International AIDS Conference on Thursday. A secondary analysis of 48-week data from the ACTG5202 study reasserted that the dual-nucleoside backbone of abacavir plus 3TC was more likely to lead to toxicity and earlier virologic failure than tenofovir plus FTC. However, a presentation from GlaxoSmithKline (GSK) indicated that, when data from other well-designed clinical trials was analysed using the same study endpoints as ACTG5202, abacavir/3TC proved just as tolerable and effective as tenofovir/FTC.  
]]></description><category>Conference news</category><category>Starting treatment news</category><category>Mexico 2008</category></item><item><title><![CDATA[Two novel immune therapies in early investigation: autologous dendritic cells and CD4 zeta gene-modified T cells]]></title><link>http://www.aidsmap.com/en/news/312C77E1-F7C6-42B7-8B7F-978008A1A38C.asp</link><author>Derek Thaczuk</author><guid isPermaLink="false">312C77E1-F7C6-42B7-8B7F-978008A1A38C</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Immune cells extracted from individuals and then modified to enhance the individual immune response to HIV infection, appear to be a safe and feasible approach to HIV treatment, according to several reports this week at the XVII International AIDS Conference.
]]></description><category>Basic science news</category><category>New drugs news</category><category>Conference news</category><category>Mexico 2008</category></item><item><title><![CDATA[Treatment as prevention tool: enough evidence to say it works, says IAS president]]></title><link>http://www.aidsmap.com/en/news/30D49BD7-41FC-4E0D-AEBD-A210794D0533.asp</link><author>Keith Alcorn</author><guid isPermaLink="false">30D49BD7-41FC-4E0D-AEBD-A210794D0533</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[While experts are at loggerheads over the recent statement that HIV-positive heterosexual individuals who have undetectable viral load and no other sexually transmitted infections, should not be considered at risk of transmitting HIV to others, there was a striking degree of unanimity among a range of experts at the XVII International AIDS Conference that expanding the number of people on antiretroviral treatment will reduce the number of new infections at a population level.
]]></description><category>Conference news</category><category>Mexico 2008</category><category>Prevention news</category></item><item><title><![CDATA[Tenofovir kidney toxicity most likely with high blood pressure medications and PIs ]]></title><link>http://www.aidsmap.com/en/news/7686386E-E46F-4927-B43E-BC6D94AD9245.asp</link><author>Derek Thaczuk</author><guid isPermaLink="false">7686386E-E46F-4927-B43E-BC6D94AD9245</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Kidney toxicity is most likely to occur in patients taking tenofovir if they are controlling high blood pressure with potentially kidney-toxic drugs, and also taking protease inhibitors, delegates at the XVII International AIDS Conference heard on Wednesday.
]]></description><category>Conference news</category><category>Mexico 2008</category></item><item><title><![CDATA[Skills-building behavioural interventions advocated for reducing alcohol-related HIV risk in South Africa]]></title><link>http://www.aidsmap.com/en/news/372F541A-3B00-4FC8-B1ED-CA091722611C.asp</link><author>Gus Cairns</author><guid isPermaLink="false">372F541A-3B00-4FC8-B1ED-CA091722611C</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Findings from a South African study presented on Wednesday at the XVII International AIDS Conference suggest that people whose alcohol consumption puts them at higher risk of HIV infection may benefit from skills-building risk reduction interventions.
]]></description><category>Africa news</category><category>Conference news</category><category>Mexico 2008</category><category>Prevention news</category></item><item><title><![CDATA[Criminal HIV transmission and exposure laws spreading around the world ‘like a virus’]]></title><link>http://www.aidsmap.com/en/news/B250DD99-C534-4C29-A078-EDF602EFB615.asp</link><author>Edwin J. Bernard</author><guid isPermaLink="false">B250DD99-C534-4C29-A078-EDF602EFB615</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Concern over the growing international trend towards the criminalisation of HIV transmission or exposure was documented in a Wednesday morning session at the XVII International AIDS Conference that highlighted “criminalisation creep” in Europe and Central Asia as well as the rapid spread of “highly inefficient laws” in West and Central Africa. 
]]></description><category>Africa news</category><category>HIV and the law news</category><category>Mother-to-child transmission news</category><category>Women and HIV news</category><category>Mexico 2008</category><category>World policy News</category><category>Eastern Europe and Russia news</category></item><item><title><![CDATA[Prevention – there will be no magic bullet, we need ‘combination prevention’]]></title><link>http://www.aidsmap.com/en/news/851AA401-037F-44E8-8115-6320059C02D7.asp</link><author>Roger Pebody</author><guid isPermaLink="false">851AA401-037F-44E8-8115-6320059C02D7</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Whether described as “combination prevention” or “highly active HIV prevention”, the emphasis at the International AIDS Conference in Mexico City has been on the need for multi-pronged prevention programmes. This was especially the case at a special session convened by The Lancet on August 5th, where some of the world’s leading researchers called for HIV prevention efforts to be redoubled, in a manner equivalent to the campaign to provide universal access to HIV treatment.
]]></description><category>Conference news</category><category>World policy News</category><category>Mexico 2008</category><category>Prevention news</category></item><item><title><![CDATA[AIDS in 2031: where will we be?]]></title><link>http://www.aidsmap.com/en/news/207D54F8-7DE7-46FC-B07B-73712483E5AD.asp</link><author>Keith Alcorn</author><guid isPermaLink="false">207D54F8-7DE7-46FC-B07B-73712483E5AD</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[AIDS experts looking towards the state of the epidemic in 2031 warned the XVII International AIDS Conference today that massive investment is needed to scale up the manufacture of antiretroviral drugs for up to 110 million people, and that international donors need to think in terms of `pension fund` type provision to plan for the scale of antiretroviral provision that will be needed by 2031.
]]></description><category>Conference news</category><category>Treatment access news</category><category>Mexico 2008</category><category>World policy News</category></item><item><title><![CDATA[Major prevention success for sex workers and men who have sex with men in India]]></title><link>http://www.aidsmap.com/en/news/806EBC37-3E62-41DD-9D21-F8C7D395077D.asp</link><author>Roger Pebody</author><guid isPermaLink="false">806EBC37-3E62-41DD-9D21-F8C7D395077D</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[A comprehensive HIV prevention programme targeted at female sex workers and men who have sex with men in India has had a major impact on reported condom use and incidence of sexually transmitted infections, according to the evaluation results presented by Alvaro Bernejo of the International HIV/AIDS Alliance at the International AIDS Conference in Mexico City on August 6th.
]]></description><category>HSV-2</category><category>Conference news</category><category>Mexico 2008</category><category>Prevention news</category><category>Asia and Pacific news</category></item><item><title><![CDATA[Raltegravir versus efavirenz in treatment-naïves at 96 weeks: continued efficacy and fewer adverse effects]]></title><link>http://www.aidsmap.com/en/news/82A67A30-B689-46D7-9BAB-2DE43B46AA8C.asp</link><author>Derek Thaczuk</author><guid isPermaLink="false">82A67A30-B689-46D7-9BAB-2DE43B46AA8C</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[The integrase inhibitor raltegravir continues to show strong efficacy "almost identical" to that of efavirenz at 96 weeks, in combination with tenofovir and 3TC, and a side-effect profile that continues to be favourable, Dr Marty Markowitz of the Aaron Diamond AIDS Research Center reported on Tuesday at the XVII International AIDS Conference in Mexico City.
]]></description><category>New drugs news</category><category>Conference news</category><category>Mexico 2008</category></item><item><title><![CDATA[Treatment outcomes in Latin America, China and Botswana: successes and shortfalls]]></title><link>http://www.aidsmap.com/en/news/6F1E37FE-78E0-4B10-BD34-3BD292114125.asp</link><author>Derek Thaczuk</author><guid isPermaLink="false">6F1E37FE-78E0-4B10-BD34-3BD292114125</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Dramatic benefits have come from antiretroviral therapy rollout programmes in resource-limited settings and around three million people are now receiving antiretroviral therapy in low- and middle-income countries. However, such programmes are vulnerable and depend on many factors for their continued success. Significant disparities are being seen in results between and within different geographical areas and populations, the XVII International AIDS Conference heard on Monday.
]]></description><category>Africa news</category><category>Latin America news</category><category>Conference news</category><category>Asia and Pacific news</category><category>Treatment access news</category><category>Mexico 2008</category></item><item><title><![CDATA[Efavirenz superior to lopinavir/ritonavir in very advanced HIV, Mexican trial shows]]></title><link>http://www.aidsmap.com/en/news/D40B01D3-5F8F-42BC-AAFC-4DEED6191DB1.asp</link><author>Keith Alcorn</author><guid isPermaLink="false">D40B01D3-5F8F-42BC-AAFC-4DEED6191DB1</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Efavirenz treatment results in a significantly higher rate of viral suppression after 48 weeks when compared to lopinavir/ritonavir, investigators of a randomised study among Mexican patients with very advanced HIV disease reported on Tuesday at the XVII International Conference on AIDS in Mexico City.
]]></description><category>Conference news</category><category>Starting treatment news</category><category>Mexico 2008</category></item><item><title><![CDATA[Infants starting HIV treatment less likely to completely suppress viral load]]></title><link>http://www.aidsmap.com/en/news/52AC76B6-C4C9-4631-A0A0-62215D35B93D.asp</link><author>Theo  Smart</author><guid isPermaLink="false">52AC76B6-C4C9-4631-A0A0-62215D35B93D</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[While antiretroviral therapy is a lifesaving intervention recommended for all HIV-positive infants in resource-limited settings, younger children who begin antiretroviral therapy do not appear to be as likely to suppress viral load as children who begin treatment at a later age, according to findings of a South African study presented at the International AIDS Conference in Mexico City on August 4th. 
]]></description><category>Africa news</category><category>Children and HIV news</category><category>Conference news</category><category>Mexico 2008</category></item><item><title><![CDATA[Slowing CD4 cell decline with IL-2 allows HIV treatment to be deferred by 92 weeks]]></title><link>http://www.aidsmap.com/en/news/DF6686F9-37F2-448D-8EC8-688EB007FBB5.asp</link><author>Derek Thaczuk</author><guid isPermaLink="false">DF6686F9-37F2-448D-8EC8-688EB007FBB5</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Findings from ANRS 119, the Interstart trial, show that it may be possible to defer antiretroviral treatment for nearly two years by using a limited number of short courses of interleukin-2 to keep CD4 cell counts above the recommended threshold for antiretroviral treatment initiation, Jean-Michel Molina of the University of Paris reported at the XVII International AIDS Conference in Mexico City on Tuesday. 
]]></description><category>Conference news</category><category>New drugs news</category><category>Starting treatment news</category><category>Mexico 2008</category></item><item><title><![CDATA[Circumcision will halve HIV rates but may take decades to reach full impact]]></title><link>http://www.aidsmap.com/en/news/B0CE9F2C-6143-49AD-9DCC-74F2C8200460.asp</link><author>Gus Cairns</author><guid isPermaLink="false">B0CE9F2C-6143-49AD-9DCC-74F2C8200460</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Tripling the rate of male circumcision in a country with a current circumcision rate of 25% and a high rate of heterosexually-acquired HIV will eventually halve HIV incidence, a mathematical model by Richard White of the London School of Hygiene and Tropical Medicine has shown. 
]]></description><category>Africa news</category><category>Conference news</category><category>Mexico 2008</category><category>Circumcision news</category><category>Prevention news</category></item><item><title><![CDATA[Widespread NRTI and NNRTI resistance seen in Malawian patients failing first-line antiretroviral therapy]]></title><link>http://www.aidsmap.com/en/news/6173CF78-D259-45DA-8A94-EE0AF060D537.asp</link><author>Derek Thaczuk</author><guid isPermaLink="false">6173CF78-D259-45DA-8A94-EE0AF060D537</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[To date, few data have been reported on emerging drug resistance patterns in Africa. In an oral presentation at the International AIDS Conference in Mexico City on August 5th, delegates heard that drug resistance was widespread among people failing antiretroviral treatment in Malawi, due to lack of viral load testing to identify virologic treatment failure. 
]]></description><category>Changing treatments news</category><category>Africa news</category><category>Conference news</category><category>Mexico 2008</category><category>Resistance news</category></item><item><title><![CDATA[High HIV incidence among young Thai men who have sex with men]]></title><link>http://www.aidsmap.com/en/news/3E2E005C-808D-40ED-9BDD-08785AFDE2FB.asp</link><author>Roger Pebody</author><guid isPermaLink="false">3E2E005C-808D-40ED-9BDD-08785AFDE2FB</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[The first ever study of the incidence of new HIV infections among men who have sex with men in Thailand has shown that each year 5% acquire HIV, reported Wipas Wimonsate from the Thai Ministry of Public Health at the International AIDS Conference in Mexico City on August 4th. The men recruited to this study will continue to be followed for three years, and the data from the study will help the planning of HIV prevention in this group.
]]></description><category>Conference news</category><category>Gay men news</category><category>Prevention news</category><category>Mexico 2008</category></item><item><title><![CDATA[HIV programme in Western Kenya successfully delivers isoniazid preventive therapy to thousands]]></title><link>http://www.aidsmap.com/en/news/B5E8F5AA-1815-4552-82B4-307E953B64EF.asp</link><author>Theo  Smart</author><guid isPermaLink="false">B5E8F5AA-1815-4552-82B4-307E953B64EF</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Isoniazid preventive therapy (IPT) can be successfully delivered by HIV treatment programmes to thousands of people according to a report from the USAID-AMPATH care programme in Western Kenya presented Monday at AIDS 2008 in Mexico City. Between September 2004, and February 2007, the programme put close to 10,000 people with HIV on IPT, achieving high rates of treatment completion with lower rates of TB in people who completed treatment.
]]></description><category>Conference news</category><category>Mexico 2008</category><category>Tuberculosis news</category></item><item><title><![CDATA[Swiss statement that ‘undetectable equals uninfectious’ creates more controversy in Mexico City]]></title><link>http://www.aidsmap.com/en/news/CB3AEAB0-8910-4B75-A6B1-3AEBB1413D2A.asp</link><author>Edwin J. Bernard</author><guid isPermaLink="false">CB3AEAB0-8910-4B75-A6B1-3AEBB1413D2A</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Science took a back seat to politics during one of the most controversial sessions of the XVII International AIDS Conference in Mexico City – one that took place hours before the conference had officially opened. At a specially convened satellite event, seven influential panellists discussed the implications of the Swiss Federal AIDS Commission’s controversial January statement – that an undetectable viral load in the blood renders an individual uninfectious, under optimal conditions.
]]></description><category>Africa news</category><category>HIV and the law news</category><category>HSV-2</category><category>Conference news</category><category>Developed world news</category><category>Gay men news</category><category>Starting treatment news</category><category>HIV and sexual health news</category><category>World policy News</category><category>Treatment access news</category><category>Community involvement news</category><category>Prevention news</category><category>Mexico 2008</category></item><item><title><![CDATA[Who defines ‘Positive prevention’?]]></title><link>http://www.aidsmap.com/en/news/7CEF6ED1-0E41-483B-ACE2-5D67B0D1A786.asp</link><author>Gus Cairns</author><guid isPermaLink="false">7CEF6ED1-0E41-483B-ACE2-5D67B0D1A786</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Structured, theory-based prevention programmes for people with HIV can be very effective, the XVII World AIDS Conference heard on Monday, with one programme reporting a 67% decline in risk in gay men given peer training. But it also heard that there is disagreement among HIV-positive activists as to whether people with HIV should be targets for interventions to reduce HIV transmission at all.
]]></description><category>Conference news</category><category>Mexico 2008</category><category>Prevention news</category></item><item><title><![CDATA[South African men with genital ulcers have very high incidence of HIV and should be a target of prevention interventions]]></title><link>http://www.aidsmap.com/en/news/AB6BB4B0-A0B6-4038-9AB0-780ECC59888B.asp</link><author>Roger Pebody</author><guid isPermaLink="false">AB6BB4B0-A0B6-4038-9AB0-780ECC59888B</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Almost two thirds of South African men presenting with genital ulcer disease are already HIV-positive, and a further 12% of the HIV-negative men acquire HIV within the next month, according to a study presented at the International AIDS Conference in Mexico City on August 5th. The researchers concluded that men with genital ulcer disease should be targeted for HIV testing and prevention interventions. 
]]></description><category>Africa news</category><category>Prevention news</category><category>Mexico 2008</category><category>HIV and sexual health news</category></item><item><title><![CDATA[HIV-1 subtype, genital ulcer disease influence risk of HIV transmission among heterosexual couples ]]></title><link>http://www.aidsmap.com/en/news/FE354E0C-BD42-416B-ADB8-FBEEF2EEA2F1.asp</link><author>Liz Highleyman</author><guid isPermaLink="false">FE354E0C-BD42-416B-ADB8-FBEEF2EEA2F1</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Viral subtype may influence the likelihood of HIV transmission between heterosexual couples, and concurrent genital ulcer disease (GUD) plays a clear role, according to a study from Uganda presented yesterday at the XVII International AIDS Conference in Mexico City.
]]></description><category>HSV-2</category><category>Conference news</category><category>Mexico 2008</category><category>Prevention news</category></item><item><title><![CDATA[Earlier ART benefits HIV/TB co-infected patients in Iran; Argentinian study yields uncertain results]]></title><link>http://www.aidsmap.com/en/news/EBFBC1D6-7FA2-409B-BC01-0DB0FE8AEA1E.asp</link><author>Derek Thaczuk</author><guid isPermaLink="false">EBFBC1D6-7FA2-409B-BC01-0DB0FE8AEA1E</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Iranian and Argentinean researchers presented contradictory evidence on the risks of delaying antiretroviral therapy in people receiving TB treatment at the XVII International AIDS Conference in Mexico City, during a poster discussion on TB and HIV. 
]]></description><category>Adherence news</category><category>Conference news</category><category>Mexico 2008</category><category>Tuberculosis news</category></item><item><title><![CDATA[Microfinance project reduces HIV risk in South African women, gold standard trial shows]]></title><link>http://www.aidsmap.com/en/news/C561AE87-0EFE-4873-811A-21E05A714AF8.asp</link><author>Keith Alcorn</author><guid isPermaLink="false">C561AE87-0EFE-4873-811A-21E05A714AF8</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[A microfinance and training project designed to empower South African women was associated with a significant reduction in HIV risk behaviour and partner violence over two years of follow-up, delegates heard at the XVII International AIDS Conference in Mexico City on Monday.
]]></description><category>Conference news</category><category>Women and HIV news</category><category>Mexico 2008</category><category>Prevention news</category></item><item><title><![CDATA[Lipodystrophy common, but does not affect adherence in Thai patients]]></title><link>http://www.aidsmap.com/en/news/D47C2EEF-78F2-454F-937D-3DCE46F24E2B.asp</link><author>Keith Alcorn</author><guid isPermaLink="false">D47C2EEF-78F2-454F-937D-3DCE46F24E2B</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Lipodystrophy is common among Thai patients taking first-line therapy but has not affected adherence to treatment, a Thai research group reported on Monday at the XVII International AIDS Conference in Mexico City. However, the condition is not being managed by reducing the d4T dose as recommended by the World Health Organization in 2007.
]]></description><category>Adherence news</category><category>Lipodystrophy news</category><category>Conference news</category><category>Asia and Pacific news</category><category>Mexico 2008</category></item><item><title><![CDATA[Invisible men: action urged for gay men in the global South]]></title><link>http://www.aidsmap.com/en/news/9E5F0B85-E13B-43B6-9E85-4FFD9199791A.asp</link><author>Gus Cairns</author><guid isPermaLink="false">9E5F0B85-E13B-43B6-9E85-4FFD9199791A</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[“This epidemic never ceases to surprise us. In every major city in Asia we have looked at, there are now epidemics of HIV among men who have sex with men (MSM) – epidemics that remind me of what we saw in the USA and Europe in the 1980s. HIV is now rising as fast in those men as it was then. This was the warning given by Peter Piot, retiring Director of UNAIDS, at the satellite meeting on gay men/MSM preceding the 2008 World AIDS Conference in Mexico City.
]]></description><category>Conference news</category><category>Gay men news</category><category>Mexico 2008</category><category>Prevention news</category></item><item><title><![CDATA[Switch to atazanavir does not reduce belly fat]]></title><link>http://www.aidsmap.com/en/news/6FCC1775-1945-4CF9-9741-6F781F4EFC44.asp</link><author>Keith Alcorn</author><guid isPermaLink="false">6FCC1775-1945-4CF9-9741-6F781F4EFC44</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Switching from other protease inhibitors to atazanavir/ritonavir does not significantly  reduce visceral fat accumulation in the abdomen – a feature of the lipodystrophy syndrome - according to 48-week results of a randomised trial presented on Monday at the XVII International AIDS Conference in Mexico City.
]]></description><category>Lipodystrophy news</category><category>Conference news</category><category>Mexico 2008</category></item><item><title><![CDATA[US HIV incidence 40% higher than previous estimates, new test shows]]></title><link>http://www.aidsmap.com/en/news/BE667F0D-2794-45A0-98D6-E648A79F4260.asp</link><author>Liz Highleyman</author><guid isPermaLink="false">BE667F0D-2794-45A0-98D6-E648A79F4260</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[Based on a new testing technique that can distinguish recent from long-standing HIV infections, the U.S. Centers for Disease Control and Prevention (CDC) now estimates that there were 56,300 new HIV infections in the U.S. in 2006—about 40% higher than the previous estimate. The figures were released on August 2, in advance of the XVII International AIDS Conference in Mexico City, and published in the August 6 edition of the Journal of the American Medical Association.
]]></description><category>Conference news</category><category>Gay men news</category><category>Mexico 2008</category><category>Prevention news</category></item><item><title><![CDATA[Malawi MSM survey reveals very high HIV acquisition and transmission risks]]></title><link>http://www.aidsmap.com/en/news/EFF8CFC9-B743-4231-BBAE-7565F7F56F86.asp</link><author>Gus Cairns</author><guid isPermaLink="false">EFF8CFC9-B743-4231-BBAE-7565F7F56F86</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[The first figures released from a series of systematic surveys of men who have sex with men in southern Africa has revealed, at least in the first site analysed in Malawi, very high levels of behaviours likely to enhance the spread of HIV. The figures were presented at the meeting of the Global Forum on Men who have Sex with Men and HIV, a satellite conference on gay men and MSM attended by nearly 500 people in the two days preceding the World AIDS Conference.
]]></description><category>Africa news</category><category>Gay men news</category><category>Conference news</category><category>Prevention news</category><category>Mexico 2008</category></item><item><title><![CDATA[World AIDS conference comes to Latin America]]></title><link>http://www.aidsmap.com/en/news/543973B9-F112-4036-B16D-A6139D9FCD27.asp</link><author>Keith Alcorn</author><guid isPermaLink="false">543973B9-F112-4036-B16D-A6139D9FCD27</guid><pubDate>Sat, 22 Nov 2008 00:27:58 GMT</pubDate><image /><description><![CDATA[The first International AIDS Conference to focus on Latin America will open tomorrow in Mexico City, the largest city in the Spanish-speaking world. The conference, held every two years, is the biggest gathering of AIDS experts, advocates, people with HIV and physicians, and this year it has attracted more than 22,000 delegates.
]]></description><category>Latin America news</category><category>Conference news</category><category>Mexico 2008</category></item></channel></rss>